SpecificiT Pharma Inc. logo

SpecificiT Pharma Inc.

SpecificiT Pharma develops personalized hematological cancer immunotherapies by using Minor Histocompatability Antigens (MiHAs) which enable donor T-cells to be safely directed to eliminate cancer cells following allogeneic hematopoietic cell transplantation (AHCT).

0
Management
0
Technology
0
Deals/Partnering
0
Research Pipeline
0
Funding
BioStartup's Score 0 / 50

KEY DETAILS

Websitehttps://www.specificitpharma.com
Founded2016
Disease Focus
Development Stage
STOCK CODENon Listed
Address
1010 Sherbrooke Street West, Suite 408, QC, H3A 2R7
Montreal
Canada
Email
Contact Number

[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://in.linkedin.com/company/specificit-pharma-inc” connections=”true” suffix=””]

SpecificiTs unique approach is centered on the use of Minor Histocompatability Antigens (_MiHAsÓ) which enable donor T-cells to be safely directed to eliminate cancer cells in a patient.

In Sep 2017, SpecificiT Pharma completed seed financing by existing shareholder AmorChem, along with new partners, Sanderling Ventures and Accel-Rx Health Sciences Accelerator.